JACOBIO PHARMACEUTICALS GROUP CO., LTD.
加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE IIA CLINICAL TRIAL OF BET INHIBITOR JAB-8263 IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN CHINA

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**" or "**Jacobio**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the Company has completed the first patient dosage in the phase IIa clinical trial of its self-developed BET Inhibitor JAB-8263 in the treatment of rheumatoid arthritis (RA) in China. This marks the formal expansion of JAB-8263 from the field of oncology to the field of autoimmune diseases. This is also the first BET inhibitor exploring the RA indication worldwide.

Previously, JAB-8263 has generated positive clinical data in oncology indications. Nearly 100 patients with malignant tumours have been enrolled in the clinical trials across China and the United States, which has demonstrated its favourable safety profile. At the 66th American Society of Hematology (ASH) Annual Meeting held in 2024, the Company presented preliminary results from the Phase I clinical trial of JAB-8263 for myelofibrosis (MF). The data demonstrated that JAB-8263 is well tolerated and yields encouraging efficacy signals.

JAB-8263 is a potent BET inhibitor independently discovered and developed by Jacobio with global intellectual property rights. Unlike other marketed therapeutics for autoimmune diseases, BET proteins play a vital role in autoimmune disorders via epigenetic regulation. Preclinical studies suggest that BET inhibitors potentially possess important therapeutic value in rheumatoid arthritis and other autoimmune diseases as well as to avoid the safety risk associated with existing oral targeted immunosuppressants. As an oral small-molecule agent, it is expected to improve patients' long-term treatment outcomes by modulating epigenetic status.

Latest research suggests that an optimal therapeutic for autoimmune diseases should fulfil three core requirements: inhibiting cytokine production, resetting immune homeostasis and facilitating tissue repair, whilst maintaining a favourable safety profile. Compared with existing drugs for autoimmune diseases, JAB-8263 features distinct advantages including multi-targeted mechanisms and a superior safety profile.

The Phase IIa clinical trial will primarily evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of JAB-8263 in patients with rheumatoid arthritis.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around targeted oncology and tumor immunotherapy with pipelines in KRAS, Sting, P53 and MYC pathways. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our targeted antibody-drug conjugate (tADC) and immunostimulatory antibody-drug conjugate (iADC) Platform loaded with targeted drugs and immune recruiters as payloads.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that JAB-8263 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, July 27, 2026

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.